Crescent Biopharma, Inc.
CBIOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 19, 2026 | UBS | $36.00(+204%) | $11.86 | StreetInsider | |
| Oct 6, 2026 | H.C. Wainwright | $36.00(+158%) | $13.94 | TheFly | |
| Feb 26, 2026 | Stifel Nicolaus | Stephen Willey | $29.00(+135%) | $12.35 | StreetInsider |
| Jan 28, 2026 | Piper Sandler | $35.00(+211%) | $11.27 | TheFly | |
| Jan 21, 2026 | Guggenheim | Brad Canino | $35.00(+150%) | $13.98 | TheFly |
| Dec 4, 2025 | Stifel Nicolaus | Stephen Willey | $32.00(+146%) | $12.99 | TheFly |
| Aug 25, 2025 | Jefferies | $26.00(+77%) | $14.70 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Oct 19, 2026 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Oct 6, 2026 |
| Wedbush | maintain | Outperform | Sep 14, 2026 |
| Wedbush | maintain | Outperform | Aug 27, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jun 1, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 2, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 27, 2025 |
| TD Cowen | downgrade | Buy →Hold | Jul 26, 2024 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | May 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 27, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 3, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 4, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 30, 2023 |
| HC Wainwright & Co. | maintain | Buy | Feb 16, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 4, 2022 |
| Jefferies | upgrade | Hold →Buy | Nov 12, 2021 |
| Roth Capital | maintain | Buy | Dec 8, 2020 |
| HC Wainwright & Co. | maintain | Buy | Jul 31, 2020 |
| H.C. Wainwright | maintain | Buy | Mar 2, 2020 |
| Roth Capital | maintain | Buy | Nov 14, 2019 |
| SunTrust Robinson Humphrey | downgrade | Buy →Hold | Aug 5, 2019 |
| Jefferies | downgrade | Buy →Hold | Aug 5, 2019 |
| Piper Sandler | downgrade | Overweight →Neutral | Aug 5, 2019 |
| Piper Jaffray | downgrade | Overweight →Neutral | Aug 5, 2019 |
| PiperJaffray | maintain | Overweight | Apr 12, 2019 |
Earnings History
Next report: Mar 4, 2027 · EPS est. $-0.70| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Jul 30, 2026 | $-0.74 | $-0.74 | — | $357.1K |
| Apr 29, 2026 | $-0.70 | $-0.85 | $1.0M | $357.1K |
| Feb 26, 2026 | $-4.01 | $-2.22 | $10.8M | $10.0M |
| Nov 6, 2025 | $-1.27 | $-1.01 | — | $30.6M |
| Aug 6, 2025 | $-4.93 | $-2.69 | — | — |
| May 14, 2025 | $-0.04 | $-5.00 | — | — |
| Feb 13, 2025 | $-0.11 | $-0.16 | — | — |
| Nov 13, 2024 | $-0.15 | $-0.11 | — | — |
News
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 11,775 shares of the Company's ordinary shares to one non-executive employee as an equity inducement award under the …
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November:
Crescent Biopharma (NASDAQ: CBIO - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a report released on Monday, MarketBeat.com reports. They presently have a $36.00 target price on the biopharmaceutical company's stock. HC Wainwright's price objective indicates a potential upside of 186.33% from the stock's previous close. Other
More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track to report initial monotherapy data from ASCEND in Q1 2027, including antitumor response for a first-line non-small cell lung cancer (NSCLC) cohort Enrolling patients in CR-001 plus standard of care chemotherapy combinations from ASCEND expansion cohorts in several solid tumor types in treatment-naive and previously treated patients, including first-line NSCLC, colorectal, bi…
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 81,525 shares of the Company's ordinary shares to six non-executive employees as equity inducement awards under the C…
Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026
WALTHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 31,200 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the …
Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) insider Barbara Bispham sold 620 shares of Crescent Biopharma stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $17.90, for a total transaction of $11,098.00. Following the transaction, the insider owned 18,710 shares of the company's stock, valued at
Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) CEO Joshua Brumm sold 1,610 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $17.90, for a total value of $28,819.00. Following the sale, the chief executive officer owned 279,602 shares in the company,
Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) insider Ellie Im sold 623 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $17.90, for a total value of $11,151.70. Following the completion of the sale, the insider directly owned 21,446 shares in the company,
Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) CFO Richard Scalzo sold 568 shares of Crescent Biopharma stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $17.90, for a total value of $10,167.20. Following the completion of the transaction, the chief financial officer owned 19,730 shares of
Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) insider Jan Pinkas sold 658 shares of the company's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $17.90, for a total transaction of $11,778.20. Following the transaction, the insider owned 21,581 shares in the company, valued at $386,299.90.
Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) COO Jonathan McNeill sold 731 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $17.90, for a total value of $13,084.90. Following the completion of the transaction, the chief operating officer owned 138,427 shares of the
Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) COO Jonathan McNeill sold 3,839 shares of the business's stock in a transaction on Friday, September 18th. The shares were sold at an average price of $16.71, for a total transaction of $64,149.69. Following the transaction, the chief operating officer directly owned 134,588 shares of the company's
Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) CEO Joshua Brumm sold 7,837 shares of the business's stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $16.71, for a total value of $130,956.27. Following the sale, the chief executive officer owned 271,765 shares of the company's stock,
Vir Biotechnology (NASDAQ: VIR - Get Free Report) and Crescent Biopharma (NASDAQ: CBIO - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Valuation and Earnings This table compares Vir
Crescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 58,650 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the …
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September: 2026 Cantor Global Healthcare Conference, fireside chat on Thursday, September 10, 2026 at 1:35 p.m.